Evidence map›Paper›PMID 28403854›Full record

ArticleBMC musculoskeletal disorders2017

Gait characterization in golden retriever muscular dystrophy dogs using linear discriminant analysis.

Bodvaël Fraysse, Inès Barthélémy, El Mostafa Qannari, Karl Rouger, Chantal Thorin, Stéphane Blot, Caroline Le Guiner, Yan Chérel, Jean-Yves Hogrel

Open access · goldAbstract readValidation Study
In one paragraph

Article in BMC musculoskeletal disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Bodvaël FraysseAtlantic Gene Therapies, INSERM UMR 1089, Nantes, France. bodvael.fraysse@univ-nantes.fr.
Inès BarthélémyINSERM U955-E10 Biology of the NeuroMuscular System, 94000, Créteil, France.
El Mostafa QannariLUNAM University, ONIRIS, National College of Veterinary Medicine, Food Science, and Engineering, USC "Sensometrics and Chemometrics Laboratory", Nantes, France.
Karl RougerAtlantic Gene Therapies, INRA UMR 703, ONIRIS, Nantes, France.
Chantal ThorinNutrition and Endocrinology Unit, ONIRIS, National College of Veterinary Medicine, Food Science, and Engineering, Nantes, France.
Stéphane BlotINSERM U955-E10 Biology of the NeuroMuscular System, 94000, Créteil, France.
Caroline Le GuinerAtlantic Gene Therapies, INSERM UMR 1089, Nantes, France.
Yan ChérelAtlantic Gene Therapies, INRA UMR 703, ONIRIS, Nantes, France.
Jean-Yves HogrelNeuromuscular Physiology and Evaluation Lab, Institute of Myology, Paris, France.
Oniris · FRInserm · FRÉcole Nationale Vétérinaire d'Alfort · FRInstitut de Myologie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccelerometric analysis of gait abnormalities in golden retriever muscular dystrophy (GRMD) dogs is of limited sensitivity, and produces highly complex data. The use of discriminant analysis may enable simpler and more sensitive evaluation of treatment benefits in this important preclinical model.

methodsAccelerometry was performed twice monthly between the ages of 2 and 12 months on 8 healthy and 20 GRMD dogs. Seven accelerometric parameters were analysed using linear discriminant analysis (LDA). Manipulation of the dependent and independent variables produced three distinct models. The ability of each model to detect gait alterations and their pattern change with age was tested using a leave-one-out cross-validation approach.

resultsSelecting genotype (healthy or GRMD) as the dependent variable resulted in a model (Model 1) allowing a good discrimination between the gait phenotype of GRMD and healthy dogs. However, this model was not sufficiently representative of the disease progression. In Model 2, age in months was added as a supplementary dependent variable (GRMD_2 to GRMD_12 and Healthy_2 to Healthy_9.5), resulting in a high overall misclassification rate (83.2%). To improve accuracy, a third model (Model 3) was created in which age was also included as an explanatory variable. This resulted in an overall misclassification rate lower than 12%. Model 3 was evaluated using blinded data pertaining to 81 healthy and GRMD dogs. In all but one case, the model correctly matched gait phenotype to the actual genotype. Finally, we used Model 3 to reanalyse data from a previous study regarding the effects of immunosuppressive treatments on muscular dystrophy in GRMD dogs. Our model identified significant effect of immunosuppressive treatments on gait quality, corroborating the original findings, with the added advantages of direct statistical analysis with greater sensitivity and more comprehensible data representation.

conclusionsGait analysis using LDA allows for improved analysis of accelerometry data by applying a decision-making analysis approach to the evaluation of preclinical treatment benefits in GRMD dogs.

Indexed as

AccelerometryAge FactorsAnimalsClinical Decision-MakingDiscriminant AnalysisDisease Models, AnimalDisease ProgressionDogsGaitGenotypeImmunosuppressive AgentsLinear ModelsMaleMuscular Dystrophy, AnimalMuscular Dystrophy, DuchennePhenotypeImmunosuppressive AgentsAccelerometryAnimal modelDiscriminant analysisGait assessmentGRMDMuscular dystrophyTreatment evaluation

Identifiers

PMID28403854
PMCPMC5388997
OpenAlexW2605577153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.